Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 78,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was purchased at an average cost of $4.22 per share, for a total transaction of $329,160.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $12,950,973.22. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, February 5th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.14 per share, for a total transaction of $207,000.00.
  • On Friday, February 2nd, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.30 per share, for a total transaction of $236,500.00.
  • On Wednesday, January 31st, Phillip Md Et Al Frost bought 65,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.47 per share, for a total transaction of $290,550.00.
  • On Friday, January 26th, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.90 per share, for a total transaction of $269,500.00.
  • On Wednesday, January 24th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.89 per share, for a total transaction of $489,000.00.
  • On Monday, January 22nd, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.40 per share, for a total transaction of $440,000.00.

Opko Health Inc. (NASDAQ:OPK) traded down $0.23 during mid-day trading on Friday, hitting $3.80. The stock had a trading volume of 2,280,000 shares, compared to its average volume of 4,770,000. Opko Health Inc. has a 12-month low of $3.75 and a 12-month high of $8.92. The company has a current ratio of 1.66, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01. The stock has a market cap of $2,130.00, a PE ratio of -20.00 and a beta of 1.42.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03). Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The company had revenue of $263.50 million for the quarter, compared to analysts’ expectations of $319.43 million. During the same period in the previous year, the firm earned ($0.03) earnings per share. The firm’s quarterly revenue was down 11.6% on a year-over-year basis. equities analysts forecast that Opko Health Inc. will post -0.27 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of OPK. Crossmark Global Holdings Inc. purchased a new position in shares of Opko Health during the 3rd quarter valued at about $118,000. State of Alaska Department of Revenue purchased a new position in shares of Opko Health during the 4th quarter valued at about $144,000. The Manufacturers Life Insurance Company lifted its position in shares of Opko Health by 7.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 1,657 shares in the last quarter. Psagot Investment House Ltd. lifted its position in shares of Opko Health by 20.0% during the 2nd quarter. Psagot Investment House Ltd. now owns 22,862 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 3,806 shares in the last quarter. Finally, First Trust Advisors LP purchased a new position in shares of Opko Health during the 4th quarter valued at about $154,000. 22.94% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have issued reports on OPK shares. Zacks Investment Research cut Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 24th. BidaskClub cut Opko Health from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Cantor Fitzgerald set a $20.00 target price on Opko Health and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $13.34.

COPYRIGHT VIOLATION NOTICE: “Insider Buying: Opko Health Inc. (OPK) CEO Purchases 78,000 Shares of Stock” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/02/09/insider-buying-opko-health-inc-opk-ceo-purchases-78000-shares-of-stock.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.